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between acute or chronic kidney injury and kidney tumors.
However, whether these associations are linked by
causation, and in which direction, is unclear. Accumulating
data from basic and clinical research now shed light on this
issue and prompt us to propose a new pathophysiological
concept with immanent implications in the management of
patients with kidney disease and patients with kidney
tumors. As a central paradigm, this review proposes the
mechanisms of kidney damage and repair that are active
during acute kidney injury but also during persistent
injuries in chronic kidney disease as triggers of DNA
damage, promoting the expansion of (pre-)malignant cell
clones. As renal progenitors have been identified by
different studies as the cell of origin for several benign and
malignant kidney tumors, we discuss how the different
types of kidney tumors relate to renal progenitors at
specific sites of injury and to germline or somatic mutations
in distinct signaling pathways. We explain how known risk
factors for kidney cancer rather represent risk factors for
kidney injury as an upstream cause of cancer. Finally, we
propose a new role for nephrologists in kidney cancer (i.e.,
the primary and secondary prevention and treatment of
kidney injury to reduce incidence, prevalence, and
recurrence of kidney cancer).
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Kidney International (2021) 100, 55–66C ancerogenesis is a complex process involving germlineand/or somatic mutations leading to an uncontrolledexpansion of mutated cells. Frequently, this occurs in a
series of steps in which numerous combinations of mutations
only gradually pass the threshold for unrestricted cell growth.1
Tissue injury is a known trigger of cancerogenesis for 2 reasons:
(i) its potential to induce DNA damage and somatic mutations,
especially in tissue-resident long-lived stem cells2; and (ii) its
potential to promote the expansion of such mutated cells
during the process of tissue repair.3 For example, these 2
mechanisms contribute to inflammatory bowel disease–related
colorectal cancer4 and to lung cancer related to exposures to
toxic smokes and dust particulates,5 atrophic gastritis–related
gastric cancer,6 and cirrhosis-related hepatocellular carcinoma.7
Numerous epidemiologic studies report the association
between chronic kidney disease (CKD) and kidney cancer
(Table 18–15). Although both occur preferably in the second
half of life, it remains unclear whether and how these asso-
ciations are linked by causation. For example, causation may
be one way because tumor therapy, including surgery, and
antiangiogenic agents or mechanistic target of rapamycin
(mTOR) and immune checkpoint inhibitors involve an
increased risk of acute kidney injury (AKI) and CKD.16,17
Similarly, whether kidney injury causes kidney cancer is not
clear at all, although some studies suggest that kidney cancer
develops following an AKI episode or after years of CKD at
the stage of kidney failure (Table 218–25). In this review, we
discuss the role of kidney injury as a driver of kidney cancer.
Starting out with epidemiologic and genetic evidence, we
discuss the evolving experimental support for kidney injury as
a trigger of DNA damage and clonal proliferation of mutated
kidney cells in different kidney compartments, determining
the tumor histotype. We discuss the recent insights on the
putative cells of origin for benign and malignant kidney tu-
mors and explain how injury-mediated alterations in the
activation of distinct signaling pathways contribute to the
different histotypes of kidney tumors. We further explore how
the intrinsic mechanisms of kidney repair that transiently
operate on AKI episodes and that persistently operate in CKD
promote tumor growth and tumor recurrence. Finally, we
suggest that prevention of AKI and CKD is the best way to
stop renal cell carcinoma (RCC) development and avoid its
consequences. This concept of bidirectional causal55
r ev i ew AJ Peired et al.: Kidney injury and cancerrelationship between kidney disease and kidney tumors calls
for a central role of the nephrologist in prevention and
treatment of patients with kidney cancer.
The risk factors for kidney cancer are risk factors for kidney
disease
Epidemiologic studies identify associations, but without
confirming causation, such associations frequently trigger
misleading interpretations. For example, in search for the
unknown causes of kidney cancer, epidemiologic studies
identified several “risk factors” for which a direct causative
link to cancerogenesis is not always obvious (Table 326–43).
Obesity, diabetes, hypertension, smoking, nephrotoxic
drugs, and heavy metals all promote kidney injury, either
AKI or CKD, and may link indirectly to injury-related kid-
ney cancer rates.44–46 Indeed, nephrotoxic drugs and heavy
metals induce episodes of toxic AKI associated with nec-
roinflammation and oxidative stress.45 Obesity, diabetes, and
smoking are well-established risk factors for glomerular
hyperfiltration and glomerulosclerosis-related CKD,
imposing nephron loss and considerable adaptive cellular
changes in the remnant nephrons to accommodate the
metabolic needs.46 Finally, hypertension, rather than a
cause, is frequently a consequence of kidney disease and a
sensitive indicator of early CKD.44
Site-specific kidney injuries cause unique subtypes of kidney
cancer
Accumulating evidence suggests that the different subtypes of
kidney tumors originate from cells located at the site of initial
injury. In addition, the prevalence of different kidney cancer
histotypes correlates with the prevalence of specific triggers of
kidney injury.
Most frequent: clear cell carcinoma triggered by metabolic
overload of the remnant nephron’s proximal tubule in CKD (S1/S2
segment). Prospective studies suggest that CKD directlyTable 1 | Epidemiological evidence that kidney cancer associate
patients with kidney cancer
Exposure (risk factor or disease) Outcome R
Kidney cancer CKD (stage $3)
AKI (þ50% sCr) IRR,
AKI (þ50% sCr) 62
AKI-HA (severe) 13
AKI-D 1








RCC, RN vs. PN CKD (stage $3) HR
ARF HR,
AKI, acute kidney injury; ARF, acute renal failure; CKD, chronic kidney disease; CI, cumula
hospital acquired; HR, hazard ratio; IRR, incidence rate ratio; PN, partial nephrectomy; R
Analysis of the literature highlights the link between increased risk for kidney disease in
kidney cancer.
56causes kidney cancer, particularly of the clear cell RCC
(ccRCC) histotype that represents 70%–80% of kidney can-
cers. A follow-up study of 33,346 subjects, aged 26 to 61 years
at baseline with a median follow-up of 28 years, showed that a
moderate CKD at baseline increased the subsequent risk of
kidney cancer.19 Obesity and diabetes, which promote CKD,
also drive RCC development. The link between these 2 con-
ditions is represented by the metabolic overload of the cells of
proximal tubule in remnant nephrons experiencing a drasti-
cally increased single-nephron hyperfiltration (and tubular
hyperreabsorption).47 This drives chronic cortical damage
and CKD in patients with obesity and diabetes, with possible
subsequent development of ccRCC, which typically originates
from cells of the cortical proximal tubule (S1/S2 segment)47
(Figure 125,44–46,48–57).
Still frequent: papillary carcinoma triggered by ischemic ne-
crosis of proximal tubules (S3 segment). Data obtained from
Italian as well as Danish cohort studies indicate that patients
with previous AKI episodes show an increased risk of developing
papillary RCC (pRCC).25 Further multicenter analysis showed
that patients who underwent tumor resection for pRCC and
experienced a postoperative AKI episode had a higher risk of
tumor recurrence in comparison to those who did not experi-
ence a postoperative AKI, suggesting that ischemic injury pro-
motes tumor growth.25 This association was further confirmed
in an experimental model of AKI, where the authors observed
that postischemic AKI promotes long-term development of
papillary tumors in mice by activating tumor growth–
promoting pathways.25 Direct evidence of the causative link
between ischemic AKI and kidney cancer came from experi-
ments showing onset of papillary adenomas 3 to 6 months after
ischemia, which in some cases later transformed into pRCC in a
classic adenoma-carcinoma sequence.25 Papillary adenomas and
carcinomas are mostly localized in the outer stripe of the outer
medulla, where ischemic necrosis affects the cells of the S3
segment of proximal tubules25 (Figure 1).s with kidney injury: increased risk for kidney disease in
isk [95% CI] Strength of evidence Reference
21.4% Crude prevalence at diagnosis 8
2.31 [2.05–2.60] Multivariate analysis 9
.8% [57.6–67.5] 5-yr Cumulative incidence 9
.9% [12.1–15.9] 5-yr Cumulative incidence 10
.7% [1.1–2.7] 5-yr Cumulative incidence 10
40.5% 3-yr Crude prevalence 11
7.3% 32-mo Crude prevalence 12
2.1% 32-mo Crude prevalence 12
5.36 [4.37–7.24] Multivariable analysis 13
4.79 [3.37–6.82] Multivariate analysis 13
6.95 [4.82–10.1] Multivariate analysis 13
CP, 2.0% 32-mo Crude prevalence 12
CP, 33.7% Crude prevalence 14
, 1.9 [1.48–2.45] Multivariate analysis 15
1.41 [1.12–1.79] Multivariate analysis 15
tive incidence; CP, crude prevalence; ESKD, end-stage kidney disease; D, dialysis; HA,
CC, renal cell carcinoma; RN, radical nephrectomy.
patients with kidney cancer and vice versa, as well as known risk factors for CKD and
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Table 2 | Epidemiological evidence that kidney cancer associates with kidney injury: increased risk for kidney cancer in patients
with kidney disease
Exposure (risk factor or disease) Outcome Risk [95% CI] Strength of evidence Reference
CKD (stage $3) Death for kidney cancer HR, 3.30 [1.24–8.81] Multivariate analysis 18
Death for urinary tract cancer HR, 7.30 [2.48–21.46] Multivariate analysis 18
Kidney cancer HR, 3.38 [1.48–7.71] Multivariate analysis 19
CKD (stage 3A) RCC HR, 1.39 [1.22–1.58] Multivariate analysis 20
CKD (stage 3B) RCC HR, 1.81 [1.51–2.17] Multivariate analysis 20
CKD (stage 4) RCC HR, 2.28 [1.78–2.92] Multivariate analysis 20
ESKD: dialysis Kidney cancer 3.6 [3.5–3.8] Standardized incidence ratio 21
Kidney cancer 6.8 [5.1–8.9] 10-yr Standardized incidence ratio 21
RCC 4.2% 1-yr Crude prevalence 22
Oncocytomas 0.6% 1-yr Crude prevalence 22
Transplant vs. ESKD Kidney cancer HR, 0.77 [0.70–0.84] Multivariate analysis 23
Transplant RCC 5.68 [5.27–6.13] Standardized incidence ratio 24
pRCC 13.3 [11.5–15.3] Standardized incidence ratio 24
ccRCC 3.98 [3.47–4.55] Standardized incidence ratio 24
AKI pRCC OR, 3.48 [1.14–10.67] Multivariate analysis 25
ccRCC OR, 1.55 [0.51–4.67] Multivariate analysis 25
Postoperative AKI pRCC recurrence OR, 7.24 [1.65–31.86] Multivariate analysis 25
AKI, acute kidney injury; ccRCC, clear cell renal cell carcinoma; CKD, chronic kidney disease; CI, cumulative incidence; ESKD, end-stage kidney disease; HR, hazard ratio; OR,
odds ratio; RCC, renal cell carcinoma; pRCC, papillary renal cell carcinoma.
Analysis of the literature highlights the link between increased risk for kidney disease in patients with kidney cancer and vice versa, as well as known risk factors for CKD and
kidney cancer.
AJ Peired et al.: Kidney injury and cancer r ev i ewRare but specific: lithium is toxic to collecting ducts and causes
collecting duct cell–derived tumors. Lithium therapy is
associated with collecting duct toxicity, leading to nephro-
genic diabetes insipidus in up to 40% of patients.58 Studies
indicate that lithium causes the loss of the molecular water
channel aquaporin-2. Lithium also alters the Notch
pathway, which is involved in many aspects of cancer
biology59 and has an important role in regulating the
maintenance of mature renal epithelial cell states.60 Long-
term exposure to lithium leads to tubulointerstitial
nephritis and renal cysts, originating from distal tubules
and collecting ducts.58 Although long-term use of lithium
is not associated with increased cumulative risk of kidney
cancer,61 lithium-treated patients show a high risk of
developing oncocytomas/chromophobe RCC (that arise
from a common progenitor lesion62 and are histologically
and morphologically similar63) and collecting duct carci-
nomas49 (Figure 1). All these tumors originate from the
collecting duct and are reported as rare.48,49,64 However,
the Pharmacovigilance Risk Assessment Committee of the
European Medicine Agency has agreed that the evidence
is sufficient to conclude that long-term use of lithium
may induce microcysts, oncocytomas, and collecting duct
renal carcinomas (http://www.ema.europa.eu/docs/en_GB/
document_library/PRAC_recommendation_on_signal/2015/
01/WC500181043.pdf). Consistently, animals treated with
lithium presented an increased proliferation of principal
cells, as well as an increased number of intercalated cells,
possibly resulting from proliferation and differentiation of
progenitor cells or the conversion of principal cells into
intercalated cells.50 Thus, lithium therapy–related onco-
cytomas and carcinomas of the collecting duct represent
another example of injury site–specific cancerogenesis in
the kidney.Kidney International (2021) 100, 55–66Rare but specific: sickle cell anemia induces ischemic medulla
injury and medullary carcinoma. Sickle cell anemia (SCA) is
a monogenic hemoglobin disease associated with repetitive
episodes of organ hypoperfusion, tissue ischemia, and ne-
crosis.65 Sickle cell nephropathy is a serious complication of
SCA with possible progression to CKD and kidney fail-
ure.66,67 In a cross-sectional study of children with SCA,
elevated blood pressure and CKD were identified in 16.7%
and 8.3% of patients, respectively.67 Ischemia during sickling
episodes can irreversibly injure the vascular architecture of
the kidney medulla,52 sometimes followed by the develop-
ment of medullary carcinoma,52,53 an aggressive form of
kidney cancer almost exclusively associated with SCA.51
Indeed, the extreme conditions of hypoxia and hypertonic-
ity of the renal medulla, combined with regional ischemia
induced by red blood cell sickling, activate DNA repair
mechanisms to drive deletions and translocations in switch/
sucrose nonfermentable–related, matrix-associated, actin-
dependent regulator of chromatin, subfamily b, member 1
(SMARCB1), a tumor suppressor gene, which is localized in
a fragile region of chromosome 2268 (Figure 1).
This association indicates causation from injury to cancer
because cancer cannot cause SCA, hemoglobin mutations
cannot directly cause medullary cancer, and SCA-related
medullary cancer does not occur without kidney injury.52,53
Therefore, in contrast to monogenic forms of kidney cancer
that directly involve mutations in kidney cells, SCA-related
kidney cancer provides a strong clue for the role of injury
in kidney cancer, as the causative gene is absent inside kidney
cells and solely accounts for kidney injury as an upstream
event of kidney cancerogenesis. Also, the role of analgesics
and other potential third factors is unlikely in this context,
because the medullary location of injury and the cancer
subtype argue against a toxic trigger but support the causative57
Table 3 | Epidemiological evidence that kidney cancer associates with kidney injury: risk factors for kidney cancer
Exposure (risk factor or disease) Outcome Risk (95% CI) Strength of evidence Reference
Obesity
Per 5-kg/m2 BMI increase Kidney cancer (men) RR, 1.24 [1.15–1.34] Meta-analysis 26
Kidney cancer (women) RR, 1.34 [1.25–1.42] Meta-analysis 26
BMI þ 1 SD RCC OR, 1.56 [1.44–1.70] Multivariate analysis 27
25 kg/m2 # BMI < 30 kg/m2 Kidney cancer RR, 1.35 [1.27–1.43] Meta-analysis 28
BMI $ 30 kg/m2 Kidney cancer RR, 1.76 [1.61–1.91] Meta-analysis 28
BMI $ 35 kg/m2 Kidney cancer HR, 1.71 [1.06–2.79] Multivariate analysis 29
RCC (men) RR, 2.47 [1.72–3.53] Multivariate analysis 30
RCC (women) RR, 2.59 [1.70–3.96] Multivariate analysis 30
Diabetes
DM type 1–2 Kidney cancer RR, 1.42 [1.06–1.91] Meta-analysis 31
DM type 1–2 Kidney cancer (men) RR, 1.26 [1.06–1.49] Meta-analysis 31
DM type 1–2 Kidney cancer (women) RR, 1.70 [1.47–1.97] Meta-analysis 31
DM type 2 RCC HR, 1.83 [1.26–2.65] Multivariate analysis 29
Fasting insulin þ 1 SD RCC OR, 1.82 [1.30–2.55] Multivariate analysis 27
HTN
History of HTN Kidney cancer RR, 1.67 [1.46–1.90] Meta-analysis 32
History of HTN Kidney cancer (men) RR, 1.51 [1.16–1.97] Meta-analysis 32
History of HTN Kidney cancer (women) RR, 1.77 [1.50–2.08] Meta-analysis 32
Per þ10–mm Hg SYS Kidney cancer RR, 1.10 [1.05–1.14] Meta-analysis 32
Per þ10–mm Hg DIA Kidney cancer RR, 1.22 [1.10–1.34] Meta-analysis 32
BP $ 130/80 mm Hg Kidney cancer HR, 1.29 [1.23–1.35] Multivariate analysis 33
HTN with medications Kidney cancer HR, 1.74 [1.64–1.84] Multivariate analysis 33
SYS $ 160 mm Hg RCC RR, 2.48 [1.53–4.02] Multivariate analysis 34
DIA $ 100 mm Hg RCC RR, 2.34 [1.54–3.55] Multivariate analysis 34
DIA þ 1 SD RCC OR, 1.28 [1.11–1.47] Multivariate analysis 27
Drugs
Analgesics RCC OR, 1.5 [1.3–1.8] Multivariate analysis 35
Dose: 4–8 g/wk RCC OR, 1.6 [1.2–2.2] Multivariate analysis 35
Dose $8 g/wk RCC OR, 2.3 [1.7–3.1] Multivariate analysis 35
ACE-i Kidney cancer RR, 1.50 [1.01–2.23] Meta-analysis 36
Diuretics RCC OR, 1.55 [1.42–1.71] Meta-analysis 37
RCC (men) OR, 1.69 [1.34–2.13] Meta-analysis 37
RCC (women) OR, 2.01 [1.56–2.67] Meta-analysis 37
pRCC OR, 3.1 [1.4–6.7] Multivariate analysis 38
Lithium RCC (men) 7.51 [1.51–21.95] Standardized incidence ratio 39
RCC (women) 13.69 [3.68–35.06] Standardized incidence ratio 39
Smoking
All smokers RCC RR, 1.31 [1.22–1.40] Meta-analysis 40
Current smokers RCC RR, 1.36 [1.19–1.56] Meta-analysis 40
Former smokers RCC RR, 1.16 [1.08–1.25] Meta-analysis 40
Smoke $37 pack years Kidney cancer HR, 1.67 [1.16–2.42] Multivariate analysis 29
Heavy metals
Lead RCC OR, 1.55 [1.09–2.21] Multivariate analysis 41
Lead (>13.3 g/m3 yr) RCC OR, 2.25 [1.21–4.19] Multivariate analysis 41
Cadmium þ lead RCC OR, 2.77 [1.00–7.68] Multivariate analysis 41
Cadmium Kidney cancer OR, 1.47 [1.27–1.71] Meta-analysis 42
RCC OR, 1.40 [0.69–2.85] Multivariate analysis 41
Arsenic RCC OR, 2.47 [1.52–4.01] Multivariate analysis 43
ACE-i, angiotensin-converting enzyme inhibitor; BMI, body mass index; BP, blood pressure; CI, cumulative incidence; DM, diabetes mellitus; DIA, diastolic blood pressure; HR,
hazard ratio; HTN, hypertension; OR, odds ratio; RCC, renal cell carcinoma; pRCC, papillary renal cell carcinoma; RR, relative risk; SYS, systolic blood pressure.
Analysis of the literature highlights the link between increased risk for kidney disease in patients with kidney cancer and vice versa, as well as known risk factors for CKD and
kidney cancer.
r ev i ew AJ Peired et al.: Kidney injury and cancerrole of SCA-mediated ischemic injury in this location. Thus,
SCA-related kidney cancer provides another proof of concept
that kidney injury can be the trigger of kidney cancer.
Monogenic kidney cancers unravel essential signaling
pathways in kidney cancerogenesis and kidney repair
Several monogenic forms of kidney cancer show that essential
oncogenes and pathways involved in kidney cancerogenesis
are also involved in the response to kidney injury and repair.6958Von Hippel-Lindau syndrome. Mutations in the Von Hip-
pel-Lindau (VHL) tumor suppressor gene can cause an
autosomal dominant cancer syndrome with visceral cysts in
the kidney70 and kidney cancer of the clear cell type (ccRCCs)
in 24% to 45% of patients.71 Vice versa, 90% of patients with
sporadic ccRCC carry mutations leading to VHL inactiva-
tion.72 VHL is a key regulator of proteins involved in oxygen
sensing through the hypoxia-inducible factor (HIF) pathway.
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Figure 1 | Kidney injury causes benign tumor and cancer at the
site of damage. Different kidney tumor histotypes develop at the
site of damage in response to different injurious stimuli. Diabetes
and obesity promote cortical injury through metabolic overload
of proximal convoluted tubule in remnant nephrons. This drives
chronic kidney disease (CKD) and subsequent development of
clear cell renal cell carcinoma (ccRCC).44–46 Ischemic necrosis
affects cells of the S3 segment of the proximal tubule in the outer
stripe of the outer medulla, driving the development of papillary
adenomas followed by carcinomas.25 Lithium therapy increases
proliferation of cells in the collecting duct. This drives the
development of oncocytomas/chromophobe and collecting duct
carcinomas.48–50 Hypoxia and hyperosmolarity of the inner
medulla, along with ischemia induced by red blood cell sickling,
injure the vascular architecture. This affects collecting duct cells,
driving the development of medullary carcinoma.51–54 chRCC,
chromophobe renal cell carcinoma; pRCC, papillary renal cell
carcinoma; OSOM, outer stripe of outer medulla; SCA, sickle cell
anemia. ccRCC image adapted with permission by Bonert M.
2011. Available at: https://commons.wikimedia.org/wiki/User:
Nephron. Accessed October 15, 2020.55 Copyright ª 2011 Michael
Bonert. Creative Commons Attribution International License (CC
BY-SA 3.0), https://creativecommons.org/licenses/by-sa/3.0/
legalcode. Papillary adenoma image adapted with permission by
Bonert M. 2011. Available at: https://commons.wikimedia.org/
wiki/User:Nephron. Accessed October 15, 2020.55 Copyright ª 2011
Michael Bonert. Creative Commons Attribution International License
(CC BY-SA 3.0), https://creativecommons.org/licenses/by-sa/3.0/
legalcode. pRCC image adaptedwith permission by Busset C, Vijgen S,
Lhermitte B, Pu Y. A case report of papillary renal (continued)
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Kidney International (2021) 100, 55–66pseudohypoxia, promoting a unique angiogenic state and
continuous mitogenic signaling.71 Interestingly, VHL muta-
tions are highly prevalent in acquired cystic kidney disease
and in ccRCCs of patients in end-stage kidney disease, sug-
gesting that kidney injury may exert a selection pressure for
cells carrying the VHL mutations and HIF activation.73 In
addition, the metabolic stress in remnant nephrons of CKD
kidneys translates into pseudohypoxia at the cellular level that
permanently triggers HIF activation, which drives a chronic
mitogenic response to replace tubular epithelial cells suc-
cumbing to metabolic stress.74 These observations could
provide the rationale behind the association between ccRCC
and precedent CKD and explain why ccRCC derives from the
proximal convoluted tubule, where metabolic overload pri-
marily occurs. Moreover, this could explain why ccRCC, being
related to CKD that is highly prevalent in the population, is
the most frequent kidney cancer. Finally, hypoxia is the major
trigger of AKI, and the HIF pathway is strongly activated
following AKI episodes to drive the mitogenic response
needed to replace necrotic tubular epithelial cells.75
Autosomal dominant polycystic kidney disease. Mutations
in polycystic kidney disease (PKD) 1 (encoding polycystin-1)
or PKD2 (encoding polycystin-2)76 cause progressively
enlarging multiple bilateral renal cysts, which lead to kidney
failure in 50% of autosomal dominant polycystic kidney
disease (ADPKD) patients by the age of 60 years.76 Cystic and
solid kidney tumors share many similarities in terms of un-
controlled hyperplasia of renal epithelial cells77 because of
many biological similarities between ADPKD and cancer.
Available data for cancer incidence in patients with ADPKD
on dialysis,78 or after transplantation,22,79 showed an
increased risk of kidney neoplasms when compared with the
general population, but not to other patients on renal
replacement therapy without ADPKD.80 More recently, in a=
Figure 1 | (continued) cell carcinoma seeding along a
percutaneous biopsy tract. Open J Pathol. 2018;8:139–146.56
Copyright ª 2018 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution
International License (CC BY 4.0), http://creativecommons.org/
licenses/by/4.0. Oncocytoma image adapted with permission by
Bonert M. 2011. Available at: https://commons.wikimedia.org/wiki/
User:Nephron. Accessed October 15, 2020.55 Copyright ª 2011
Michael Bonert. Creative Commons Attribution International License
(CC BY-SA 3.0), https://creativecommons.org/licenses/by-sa/3.0/
legalcode. chRCC image adapted with permission by Uthman E.
Chromophobe renal cell carcinoma from a slide study set. Available
at: https://www.flickr.com/photos/euthman/4669534681/. Accessed
October 15, 2020.57 Copyright ª Ed Uthman. Creative Commons
Attribution International License (CC BY 2.0), https://
creativecommons.org/licenses/by/2.0/. Image of collecting duct
carcinoma adapted with permission by George J. Netto. Copyright ª
2016 George J. Netto. Creative Commons Attribution International
License (CC BY-SA 4.0), https://creativecommons.org/licenses/by/4.0/.
Image of renal medullary carcinoma adapted with permission by
Bonert M. 2011. Available at: https://commons.wikimedia.org/wiki/
User:Nephron. Accessed October 15, 2020.55 Copyright ª 2011
Michael Bonert. Creative Commons Attribution International License
(CC BY-SA 3.0), https://creativecommons.org/licenses/by-sa/3.0/
legalcode.
59
r ev i ew AJ Peired et al.: Kidney injury and cancerlarge cohort study conducted in Taiwan, Yu et al. reported an
increased susceptibility to kidney cancer in patients with
ADPKD before receiving renal replacement therapy, when
compared with patients without the disease but with a similar
(or no) degree of renal impairment,81 even after adjustment
for all potentially confounding factors. This supports the
hypothesis that the typical renal cystic changes in patients
with ADPKD, and particularly cluster-like papillary hyper-
plasia, may represent precancerous lesions that can evolve in
RCC, usually of the papillary histotype.82,83 Another possible
explanation is overactivation in cyst-lining epithelial cells84 of
pathways involved in kidney injury85,86 as well as in the
pathogenesis of kidney cancer (i.e., aberrant activation of
Notch and HIF-1a).87,88
Tuberous sclerosis complex. Tuberous sclerosis complex
(TSC) is an autosomal dominant disease89 due to germline
inactivating mutations of either of TSC1 (encoding hamartin)
or TSC2 (encoding tuberin) genes, forming a complex that
negatively regulates mTOR complex 1, a master regulator of
cell proliferation and differentiation.90 Manifestations include
multifocal angiomyolipomas, epithelial cysts, and RCC in up
to 5% of patients, including ccRCC,90 pRCC,90 chromophobe
RCC,91 and neuroendocrine tumors.89 Second hits can be
identified in the remaining allele of TSC1 or TSC2 in most
sporadic angiomyolipomas92 and TSC-related RCCs.93 Mu-
tations in TSC2 were observed in 60% of acquired cystic
kidney disease patients,94 suggesting a role in the development
of sporadic cysts/RCC. A strong association between age,
angiomyolipoma size, and CKD has been reported; patients
with worse CKD stage tend to be older and have more
advanced angiomyolipoma.95 CKD can develop as a conse-
quence of surgical removal of renal parenchyma because of
growth of angiomyolipoma or cysts, or acute hemorrhage
from angiomyolipomas and/or RCCs.96,97 The fact that
mTOR overactivation is responsible for renal lesions in TSC
patients is demonstrated by efficacy of treatment with mTOR
inhibitors.90,98 In addition, mTOR inhibitors improve
glomerular hypertrophy and hyperfiltration in patients with
diabetes-related CKD, suggesting that this pathway plays a
crucial role in kidney injury and repair.87,99
Hereditary pRCC. Hereditary papillary renal cancers are
observed in different rare genetic syndromes.72,100 In partic-
ular, hereditary pRCC of type 1 is associated with frequent
gains of chromosome 7 involving activating mutations of
MET.72 Likewise, somatic or germline mutations or other
genetic alterations involving the MET gene are observed in
81.3% of type 1 pRCCs.101 MET gene codes for a tyrosine
kinase receptor that binds hepatocyte growth factor that
protects against tubular cell death102 and is involved in AKI.
Kidney injury drives cancerogenesis from long-lived
progenitor cells that proliferate during kidney repair
A growing body of evidence suggests that putative renal
progenitors represent a crucial link between many types of
kidney cancer,103–105 AKI,25 and CKD.106–109 Renal pro-
genitors are immature precursors of epithelial cells localized60in the glomerulus and in all segments of the nephron and in
the collecting duct.108–115 In contrast to the highly prolifer-
ative phenotype of tissue-resident progenitors in high turn-
over organs, such as the skin or gut, renal progenitors are
mostly quiescent and show a limited spontaneous prolifera-
tive capacity to replace physiological losses of podocytes and
tubular epithelial cells.108,109,111 The traditional view of kid-
ney repair suggests that most tubular epithelial cells are
capable of proliferation, undergoing dedifferentiation on
injury.116,117 However, more recent data propose that rather a
preexisting population of putative renal progenitors undergo
clonal proliferation to replace differentiated epithelial cells
lost by detachment (e.g., podocytes) or necrosis (e.g., tubular
epithelial cells).109,111,118,119
In 2011, Lindgren et al. demonstrated a significant
similarity at transcriptional and protein levels between
renal progenitors and pRCCs as well as papillary ade-
nomas.112 A further study showed that the vascular cell
adhesion molecule-1–positive subset of renal progenitors is
endowed with high resistance to death, proliferative ca-
pacity, and multipotent differentiation capacity.108 In 2017,
Cho et al. and Goncalves et al. suggested the origin of
angiomyolipomas from multipotent kidney epithelial cells
localized inside the tubule undergoing clonal expansion in
response to TSC gene deletion.103,104 Both studies pro-
posed these cells could be renal progenitors103,104 that are
endowed with multilineage differentiation capacity113 and
that in certain conditions generate the multiple lineages
coexisting in sporadic angiomyolipomas and angiomyoli-
pomas associated with TSC103,104 (Figure 225,103–105,112). In
2018, Young et al. used single-cell RNA sequencing tech-
nology to identify the cell of origin of ccRCC and
pRCC.105 They identified the cluster proximal tubule 1,
composed of a specific subtype of scattered vascular cell
adhesion molecule-1–positive cells in convoluted proximal
tubule that matched the canonical cancer transcriptome of
pRCC and ccRCC.105 A recent reanalysis of the Young
et al. The single-cell RNA sequencing database showed that
proximal tubule 1 shared similarities with human renal
progenitor cells25 (Figure 2). Finally, by using a lineage
tracing approach based on the Confetti reporter,25 Peired
et al. directly proved that pRCC is derived by clonal
expansion of renal progenitors through an adenoma-
carcinoma sequence in response to AKI.25 Renal pro-
genitors represent a population endowed with a high
proliferative capacity and resistance to death and form
clones that generate whole tubule segments after AKI.111
Overactivation of the Notch1 pathway, which is crucially
involved in the response to AKI by promoting renal pro-
genitor proliferation,120 can also reproduce papillary ade-
nomas and pRCC formation in transgenic animal models25
(Figure 2). In the collecting ducts, renal progenitors were
proposed as the cell of origin of collecting duct–derived
oncocytoma and carcinoma RCC.50,62 Why can renal
progenitors originate multiple kidney tumors? and How is
this linked to the kidney repair process?Kidney International (2021) 100, 55–66
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Figure 2 | Mechanistic insights in the development of different types of kidney tumors. DNA damage and mutations in renal
progenitors during their clonal expansion on injury induces transformation of renal progenitors into a tumor-initiating cell. Hyperactivation or
deletion of different signaling pathways related to the repair response promotes the development of different kidney tumors.25,103–105,112
ccRCC, clear cell renal cell carcinoma; HIF, hypoxia-inducible factor; mTOR, mechanistic target of rapamycin; NICD1, Notch1 intracellular
domain; Rheb, Ras homolog enriched in brain; TSC, tuberous sclerosis complex; VHL, Von Hippel–Lindau.
AJ Peired et al.: Kidney injury and cancer r ev i ewSeveral studies have established a direct link between
resident stem cells and the pathogenesis of cancer in many
organs of the body.1–3 Pivotal examples are those of the
skin, or of the gut, where accumulation of DNA damage and
mutations in the resident stem cell initiate the oncogenic
process.1–3 Key to the process is that resident stem cells are
long-lived cells that are highly resistant to death and un-
dergo multiple cycles of cell division during life to deal with
the organ turnover or the response to injury.2 This favors
accumulation of DNA damage without cell clearance, pro-
moting cancerogenesis.1 Emerging evidence suggests similar
phenomena occur also in the kidney. Similar to resident
stem cells of other organs, renal progenitors are long-lived
cells100,111 with high resistance to death108,111,121 that un-
dergo a slow turnover during kidney lifespan109,111 and
clonally amplify, undergoing numerous divisions in
response to injury.122 Analysis of somatic mutations123 in
the subset of renal progenitors matching the proximal tu-
bule 1 phenotype found by Young et al.105 revealed an
enrichment in active chromatin, regulatory, and transcribed
regions, which increased gradually over the years, leading to
an enhanced risk of tumoral transformation.123 Ischemic
injury, exposure to nephrotoxic agents, such asKidney International (2021) 100, 55–66chemotherapeutics, is associated with single-stranded
breaks, double-stranded breaks, covalently bound chemi-
cal DNA adducts, oxidative-induced lesions, and DNA-
DNA or DNA-protein cross-links.124 Activation of tissue
injury–related pathways that push fast proliferation can
provide a second hit to the progenitors, favoring the accu-
mulation of further DNA damage and faster
carcinogenesis.125
Kidney cancer development following injury is induced
through activation of specific pathways
Each type of injury, occurring in distinct locations, prefer-
entially activates a different pathway involved in tissue injury
and repair. Consistently, many recent studies suggest that the
mechanisms leading to the transformation of renal pro-
genitors into a tumor-initiating cell are also linked to acti-
vation of signaling pathways,25 such as HIF, Notch, mTOR,
and Hippo (Figure 2). Evidence of this interconnection comes
not only from monogenic syndromes, but also from shared
risk factors as well as from animal models.
VHL-HIF pathway. The hypoxia response through the HIF
pathway plays an important role in kidney injury and repair
in patients affected by AKI and CKD75 and ccRCC.12661
r ev i ew AJ Peired et al.: Kidney injury and cancerSimilarly, in hypertensive patients, hypoxia and HIF pathway,
resulting from the constriction of blood vessels due to the
renin-angiotensin system, prostaglandins, and endothe-
lin,127,128 is a possible mechanism leading to kidney cancer
and CKD. In animal models, continuous transgenic expres-
sion of HIF-2a in tubular cells leads to renal fibrosis and
insufficiency, next to multiple renal cysts.129 Transgenic mice
with renal epithelial-specific VHL deletion failed to develop
ccRCC, suggesting that second-hit loss-of-function mutations
were needed.130 Models combining VHL deletion with PTEN,
KIF3a, TRP53, or BAP1 loss, or with activation of the intra-
cellular part of Notch1, caused the formation of simple and
atypical cystic lesions, nests of dysplastic cells with a clear
cytoplasm, or even small tumors, mimicking ccRCC precur-
sor lesions130 (Figure 2). Ultimately, the deletion of VHL
together with TRP53 and RB1 led to the formation of lesions
highly similar to human ccRCC.130 Interestingly, all pathways
activated by Pten, Kif3a, Trp53, Bap1, Rb1, and Notch1 are
involved in the process of kidney repair from injury, under-
lining the interconnection between kidney disease and kidney
cancer and suggesting that the second hit may often come
from kidney injury.25 As further evidence, adult mice with
kidney-specific inactivation of KIF3a developed cysts rapidly,
in a similar way than in VHL KIF3a double-knockout
mouse,131 only when subjected to an AKI episode.132
mTOR pathway. In diabetes mellitus, protein kinase B/mTOR
pathway, together with hyperglycemia- and hyperinsulinemia-
prompted activation of molecular pathways, contributes to
the development of RCC and diabetic kidney disease.133,134
Mutation of phosphoinositide 3-kinase–protein kinase
B–mTOR pathway genes (including PTEN, MTOR, and
PIK3CA) were frequently reported in RCC.135 In addition,
mutations in TSC1/TSC2 result in activation of mTOR signaling
through the Ras homolog enriched in brain (RHEB)–Notch-
RHEB regulatory loop,90,103,104 leading to angiomyolipoma
development (Figure 2).
Notch pathway. Aberrant Notch signaling can cause
several pathologies, including cancer, in a variety of organs,
through preservation of self-renewal and amplification of
cancer stem cells.136 Activation of the Notch pathway plays a
major role in kidney injury and repair120 but can also induce
malignant transformation of renal progenitors and develop-
ment of papillary adenomas and RCC in humans and mice25
(Figure 2). Experiments conducted in transgenic mice over-
expressing Notch1 intracellular domain in tubular cells showed
development of CKD as well as pRCC and acceleration of
cancerogenesis induced by AKI episodes, further confirming
the tight link between AKI, CKD, and pRCC.25 Notch has an
important role in control of polarity and orientation of the
mitotic spindle in several cell types.25,137–139 Indeed, aberrant
Notch activation disrupted cell polarity signaling, leading to a
notable number of abnormal mitoses in renal progenitors,
through the deregulation of pathways involved in cell cycle
checkpoints and/or mitotic spindle control.25
Hippo pathway. A deregulated Hippo pathway (yes-asso-
ciated protein 1/transcriptional coactivator with PDZ-binding62motif [YAP/TAZ] downstream target) is seen in several forms
of cystic kidney disease,140,141 in response to AKI,142 and in
several sporadic cancers, suggesting this pathway can also be a
link between cell proliferation in cyst formation and
RCC.143,144 Downregulation of Salvador homolog-1 (SAV1), a
component of the Hippo pathway, due to copy number loss is
involved in the pathogenesis of high-grade ccRCC by regulating
the proliferation of RCC cells through Hippo-YAP1
signaling.145 In addition, loss of chromosome 22, which con-
tains the tumor suppressor genes NF2 (encoding a Hippo
pathway regulator, SAV1)72 and SMARCB1 (encoding a protein
of the chromatin-modifying switch/sucrose nonfermentable
complex), is associated with sporadic pRCC.146 Finally, The
Cancer Genome Atlas analysis of pRCC revealed a high
number of mutations in both type 1 and type 2 tumors
involving Hippo signaling pathway (2.8% and 10.0%, respec-
tively).72 Targeted deletion of SAV1 in tubular epithelial cells
causes YAP1 nuclear translocation, indicative of inactive Hippo
pathway.147 Moreover, SAV1-knockout (SAV1fl/fl) mice
demonstrated morphologic abnormalities in the renal tubules,
such as large irregular nuclei, augmented cellularity, a multi-
layered epithelium, and the formation of renal cysts.147
c-Met–hepatocyte growth factor pathway. Iron overload
has been associated with carcinogenesis in humans.41 In mice,
repeated iron administration causes the intracellular release of
reactive oxygen species (i.e., a Fenton reaction) in renal
proximal tubules, which ultimately leads to a high incidence
of RCC.148 The animals presented extensive genomic alter-
ations, and 2 of the most commonly altered loci corresponded
to a MET amplification and a CDKN2a/2b deletion.148
Interestingly, tumor sizes were proportionally associated
with Met expression and/or amplification, as confirmed by
clustering analysis.148
Chromatin remodeling. Aberrations in chromatin remod-
eling proteins are associated with human diseases, including
cancer.149,150 Chromatin remodeling pathways are activated
after DNA damage, response to injury, and response to car-
cinogens, including smoking.124 In ccRCC, the pathways
involved are chromosome arm 3p genes polybromo 1
(PBRM1), SET domain-containing protein 2 (SETD2), and
BRCA-associated protein-1 (BAP1) or in SMARCB1.151,152
Loss of CDKN2A owing to mutation, deletion, or promoter
hypermethylation and mutation of TP53 were also frequently
reported in ccRCC.72,152
A call for a new role for nephrologists in kidney cancer care
Injury involving DNA damage is a known driver of malignant
transformation of proliferating cells.3 This concept derives
from irradiation-related leukemia and translates into solid
tumors arising from long-lived tissue-resident progenitor/
stem cells.2 Increasing evidence now demonstrates the same
for the non-Mendelian forms of kidney cancer.153 Sickle cell
disease–related kidney cancer is a paradigmatic example of
how repetitive ischemic kidney injury can cause kidney cancer
in the injured area of the kidney.52–54 Epidemiologic and
experimental studies now demonstrate the same for a widerKidney International (2021) 100, 55–66
AJ Peired et al.: Kidney injury and cancer r ev i ewrange of kidney cancers, and suggest a putative premalignant
condition, just about the time new strategies for kidney
cancer screening are debated.154 But why do we observe a
relatively low RCC prevalence despite the high prevalence of
CKD/AKI patients? First, benign/early forms of kidney tu-
mors go frequently undetected as they appear in older pa-
tients and take time to develop into malignant forms. As a
significant example, autopsy studies suggest that papillary
adenomas are common, with a prevalence ranging from 5%
to 10% before the age of 40 years and increasing to almost
40% above the age of 70 years.155 In addition, transition from
benign to malignant tumors represents a multihit process that
requires further environmental or genetic factors besides
CKD/AKI to fully develop.25 Finally, AKI and CKD patients
have shorter life expectancy,156 particularly when associated
with obesity and diabetes. Treatment of CKD with renin-
angiotensin system blockers not only delays CKD progres-
sion, but also lowers the incidence of RCC,157 providing the
proof of concept that treatment of kidney injury may be an
efficient approach to prevent development of kidney tumors.
Currently, the involvement of nephrologists in the man-
agement of patients with kidney cancer is often limited to
treatment of CKD after surgery and, once needed, kidney
replacement therapy. However, the injury concept of kidney
cancer implies new opportunities for nephrologists to prevent
kidney cancer and to improve outcomes of patients with
kidney cancer.
 Together with primary care physicians, nephrologists may
increase awareness for kidney disease in the community,
ameliorate blood pressure control, promote healthy life-
style education, and facilitate avoidance or correct use of
nephrotoxic medications (primary prevention).
 Nephrologists may participate in the identification of
those patients at risk who will benefit the most from
targeted kidney cancer screening programs.
 Nephrologists can contribute to limit kidney injury and,
once it occurs, provide straightforward treatment (e.g.,
by identifying the causative drug and stopping exposure
in acute toxic injury or detecting and treating subacute
and chronic kidney injury as early as possible). This may
require to first increase awareness in decision makers, to
ensure referral of patients to nephrologists as early as at
the stage of urinary abnormalities and not only once
CKD stage 3 or 4 has been reached, which is far too late
to limit the impact of kidney injury on cancerogenesis.
 Nephrologists may take a central role in secondary pre-
vention of kidney injury to limit tumor growth by
providing an optimized CKD care, by reducing CKD risk
factors, by limiting metabolic stress to remnant nephrons,
and eventually by considering tumor screening with peri-
odical ultrasound examinations in patients at greater risk.
 Nephrologists could work hand in hand with urologists
and oncologists to reduce the impact of surgical and
medical treatment on kidney injury, thereby reducing the
risk of tumor recurrence.Kidney International (2021) 100, 55–66“From kidney injury to kidney cancer” as a novel concept
may define kidney cancer as a new long-term outcome of AKI
and CKD, increase more attention on preventing kidney
injury in patients with kidney cancer, and create a new role
for nephrologists in the management of patients with kidney
cancer.DISCLOSURE
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